SA58鼻喷雾剂预防医护人员感染新型冠状病毒肺炎的安全性和有效性：一项开放标签、空白对照研究——中国内蒙古自治区呼和浩特市，2022年
Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel: An Open-Label, Blank-Controlled Study - Hohhot City, Inner Mongolia Autonomous Region, China, 2022.
作者信息
Si Shujie, Jin Canrui, Li Jianping, Cao Yunlong, Kan Biao, Xue Feng, Xie Xiaoliang Sunney, Fang Liang, Zeng Gang, Zhang Shuo, Hu Yaling, Dong Xiaoping
机构信息
Pharmacy Department, Inner Mongolia Fourth Hospital, Hohhot City, Inner Mongolia Autonomous Region, China.
Clinical Research and Development Department, Sinovac Biotech Co., Ltd., Beijing, China.
出版信息
China CDC Wkly. 2023 Mar 10;5(10):218-222. doi: 10.46234/ccdcw2023.040.
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: The active ingredient of the SA58 Nasal Spray is a broad-spectrum neutralizing antibody with a high neutralizing capacity against different Omicron sub-variants in vitro studies.
WHAT IS ADDED BY THIS REPORT?: This study demonstrated the safety and effectiveness of SA58 Nasal Spray against coronavirus disease 2019 (COVID-19) infection in medical personnel for the first time.
WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: This study provides an effective approach for the public to reduce their risk of COVID-19 infection. The findings of this research have the potential to significantly reduce the risk of infection and limit human-to-human transmission in the event of a COVID-19 outbreak.
关于该主题已知的信息有哪些？：SA58鼻喷雾剂的活性成分是一种广谱中和抗体，在体外研究中对不同的奥密克戎亚变体具有高中和能力。
本报告补充了哪些内容？：本研究首次证明了SA58鼻喷雾剂在医护人员中预防2019冠状病毒病（COVID-19）感染的安全性和有效性。
对公共卫生实践有何启示？：本研究为公众降低感染COVID-19的风险提供了一种有效方法。这项研究的结果有可能在COVID-19疫情爆发时显著降低感染风险并限制人际传播。
Zotero 插件